Asieris(SH:688176) Xin Lang Cai Jing·2025-09-26 01:35Core Viewpoint - The financial performance and trading activity of Yahuang Pharmaceutical indicate a mixed outlook, with significant revenue growth but ongoing net losses and high financing levels [1][2]. Group 1: Financial Performance - As of June 30, 2025, Yahuang Pharmaceutical reported a revenue of 130 million yuan, representing a year-on-year growth of 61.80% [2]. - The company recorded a net profit attributable to shareholders of -162 million yuan, which is an increase in losses by 11.84% compared to the previous period [2]. Group 2: Shareholder and Trading Activity - As of September 25, 2023, Yahuang Pharmaceutical's stock price decreased by 1.28%, with a trading volume of 66.05 million yuan [1]. - The company had a financing buy-in amount of 3.7364 million yuan and a financing repayment of 6.2467 million yuan on the same day, resulting in a net financing outflow of -2.5103 million yuan [1]. - The total balance of margin trading for Yahuang Pharmaceutical reached 209 million yuan, accounting for 4.45% of its market capitalization, which is above the 80th percentile level over the past year [1]. - The number of shareholders increased by 2.09% to 25,500, while the average circulating shares per person decreased by 2.05% to 14,857 shares [2]. - Among the top ten circulating shareholders, Penghua Medical Technology Stock A ranked as the fourth largest, holding 6.5441 million shares, an increase of 891,300 shares from the previous period [2].